Literature DB >> 19403769

Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.

Edward O Mason1, Linda B Lamberth, Wendy A Hammerman, Kristina G Hulten, James Versalovic, Sheldon L Kaplan.   

Abstract

Vancomycin MICs for Staphylococcus aureus isolates in a pediatric hospital with a high rate of staphylococcal infections were examined for any increase over a 7-year period. A broth microdilution scheme allowed direct comparison of the MICs generated by this method to MICs generated by Etest. MICs generated by both methods were determined with the same inoculum suspension. One hundred sixty-five S. aureus isolates were selected on the basis of the patients having been bacteremic or having received vancomycin as the definitive therapy for their infections. Of the 165 isolates, 117 were methicillin-resistant S. aureus and 48 were methicillin-susceptible S. aureus. Forty-seven were acquired in the hospital (nosocomial), 56 were community acquired, and 62 were community onset-health care associated. All but one isolate tested by broth microdilution had MICs of < 1.0 microg/ml, while 96% of these same isolates tested by Etest had MICs of > or = 1 microg/ml. A significant increase in MICs that occurred after study year 4 (2004 to 2005) was demonstrated by the Etest (P < 0.00007) but not by broth microdilution. MICs were not different for isolates of community or health care origin, regardless of methodology. The proportion of isolates with Etest MICs of < 1 and > or = 1 microg/ml between children with bacteremia for < or = 5 days and > 5 days (P = 0.3) was not different. We conclude that MICs for pediatric isolates have increased slightly since 2005 and therapeutic decisions based on vancomycin MICs need to be made by considering the methodology used.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403769      PMCID: PMC2691127          DOI: 10.1128/JCM.00407-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used.

Authors:  V Prakash; J S Lewis; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

4.  Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Three-year surveillance of community-acquired Staphylococcus aureus infections in children.

Authors:  Sheldon L Kaplan; Kristina G Hulten; Blanca E Gonzalez; Wendy A Hammerman; Linda Lamberth; James Versalovic; Edward O Mason
Journal:  Clin Infect Dis       Date:  2005-05-06       Impact factor: 9.079

6.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

7.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.

Authors:  S Boyle-Vavra; R B Carey; R S Daum
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

8.  Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.

Authors:  Ian M Gould
Journal:  Int J Antimicrob Agents       Date:  2008-04       Impact factor: 5.283

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.

Authors:  Juan-Ignacio Alós; Ana García-Cañas; Paloma García-Hierro; Francisco Rodríguez-Salvanés
Journal:  J Antimicrob Chemother       Date:  2008-06-13       Impact factor: 5.790

View more
  20 in total

1.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

2.  Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia.

Authors:  Ganesh Kumarachandran; Jennifer Kristie Johnson; Debbie-Ann Shirley; Eileen Graffunder; Emily L Heil
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

3.  Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Authors:  Mark C Kruzel; Cole T Lewis; Kerry J Welsh; Evan M Lewis; Nicola E Dundas; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

4.  Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC.

Authors:  R Khatib; K Riederer; S Shemes; A C Musta; S Szpunar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 3.267

5.  No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates.

Authors:  Jennifer L Goldman; Christopher J Harrison; Angela L Myers; Mary Anne Jackson; Rangaraj Selvarangan
Journal:  Pediatr Infect Dis J       Date:  2014-02       Impact factor: 2.129

6.  Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.

Authors:  Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.

Authors:  R A Keel; P R Tessier; J L Crandon; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

8.  Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2017-05-05       Impact factor: 7.124

9.  Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus.

Authors:  Carey-Ann D Burnham; Carol J Weber; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

10.  Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.

Authors:  J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.